Holen Sie sich die Stockscreener-App
0.3245
7.49%
0.0226
Vorhandelsmarkt:
.31
-0.0145
-4.47%
Moleculin Biotech Inc Aktie (MBRX) Neueste Nachrichten
Moleculin Biotech (MBRX) Rating Reiterated with $4.00 Price Target | MBRX Stock News - GuruFocus
Moleculin Receives Positive FDA Feedback on Pediatric Study Plan - GuruFocus
Moleculin Receives Positive FDA Feedback on Pediatric Study Plan for Annamycin in Children with R/R AML - GlobeNewswire
Moleculin Participates in Virtual Investor “What This Means” Seg - GuruFocus
Moleculin Biotech’s Annamycin Pediatric Study Approved by FDA - TipRanks
Moleculin Participates in Virtual Investor “What This Means” Segment - GlobeNewswire
Moleculin Biotech (MBRX) Advances Pediatric Cancer Treatment Study | MBRX Stock News - GuruFocus
Moleculin Receives Critical FDA Support for Children's Leukemia Treatment Development - Stock Titan
Moleculin Biotech, Inc. Advances Annamycin for Pediatric Cancer Treatment as FDA Approves Inclusion of Younger Patients in Clinical Study - Nasdaq
FDA agrees to Moleculin’s pediatric study plan for cancer drug - Investing.com
Moleculin Biotech announces ‘What This Means’ virtual investor segment - Yahoo Finance
What is HC Wainwright’s Estimate for MBRX Q2 Earnings? - Defense World
Moleculin Biotech (MBRX) Reports Positive Results from Annamycin Trial | MBRX Stock News - GuruFocus
Moleculin Participates in Virtual Investor “What This Means” Segment | MBRX Stock News - GuruFocus
Moleculin Biotech, Inc. Reports Positive Topline Results from Phase 1B/2 Trial of Annamycin for Soft Tissue Sarcoma Lung Metastases - Nasdaq
Research Analysts Offer Predictions for MBRX Q4 Earnings - Defense World
Moleculin Biotech (NASDAQ:MBRX) Stock Rating Upgraded by HC Wainwright - Defense World
Moleculin Biotech (MBRX) Receives "Buy" Rating and $4.00 Price Target | MBRX Stock News - GuruFocus
Moleculin Biotech Reports Positive Annamycin Trial Results - MSN
Moleculin Biotech (MBRX) Receives Buy Rating and $4 Price Target | MBRX Stock News - GuruFocus
Moleculin Biotech Stock (MBRX) Dives 10% on Clinical Trial Results - The Globe and Mail
Moleculin Releases On-Demand KOL Webcast to Discuss Data - GlobeNewswire
Transcript : Moleculin Biotech, Inc.Pre Recorded Shareholder/Analyst Call - MarketScreener
Moleculin Biotech, Inc. Releases On-Demand KOL Webcast to Discuss Data from its Phase 1B/2 Study of Annamycin for the Treatment of Soft Tissue Sarcoma Lung Metastases (MB-107) - MarketScreener
Moleculin Biotech Hosts Key Opinion Leaders Event - TipRanks
Moleculin Biotech Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits - Quantisnow
Moleculin Biotech (MBRX) Presents Final Data from Annamycin Clin - GuruFocus
Leading Oncologists Review Breakthrough Data from Moleculin's Sarcoma Lung Metastases Trial - Stock Titan
Moleculin announces efficacy results from trial of Annamycin for STS lung mets - Yahoo Finance
Moleculin Reports Positive Topline Efficacy Results from U.S. Ph - GuruFocus
Moleculin Biotech Shares Slump After Phase 1b/2 Trial of Annamycin Fails to Show Complete Responses - MarketScreener
Moleculin Biotech (MBRX) Reports Promising Phase 1B/2 Trial Resu - GuruFocus
Moleculin Reports Positive Topline Efficacy Results from U.S. Phase 1B/2 Clinical Trial Evaluating Annamycin for the Treatment of Soft Tissue Sarcoma Lung Metastases (MB-107) | MBRX Stock News - GuruFocus
Moleculin Biotech Reports Promising Efficacy Results for Annamycin in Phase 1B/2 Trial for Soft Tissue Sarcoma Lung Metastases - Nasdaq
Moleculin Reports Positive Topline Efficacy Results from U.S. Phase 1B/2 Clinical Trial Evaluating Annamycin for the Treatment of Soft Tissue Sarcoma Lung Metastases (MB-107) - GlobeNewswire
Moleculin Reports Positive Topline Efficacy Results from U.S. Phase 1B/2 Clinical Trial Evaluating Annamycin for the Treatment of Soft Tissue Sarcoma Lung Metastases (MB-107) - GlobeNewswire Inc.
Breakthrough: Moleculin's Cancer Drug Achieves 59.4% Clinical Benefit Rate in Late-Stage Trial - Stock Titan
Roth Capital Partners Manages New Developments for Moleculin Biotech (MBRX) | MBRX Stock News - GuruFocus
Roth Capital Partners Manages New Developments for Moleculin Bio - GuruFocus
Moleculin receives Nasdaq non-compliance notice By Investing.com - Investing.com South Africa
Moleculin Biotech Faces Nasdaq Non-Compliance Notice - TipRanks
Moleculin receives Nasdaq non-compliance notice - Investing.com
Moleculin signals first 45-patient unblinding for Phase 3 AML trial by end of 2025 as key regulatory milestones achieved - MSN
Q2 EPS Forecast for Moleculin Biotech Increased by Analyst - Defense World
Moleculin Biotech reaches agreement to amend investor warrants - MSN
MBRX stock touches 52-week low at $1.46 amid sharp yearly decline - MSN
Moleculin Announces First European Approval for Phase 3 AML Trial - MSN
Moleculin Biotech’s Earnings Call: Trials and Triumphs - TipRanks
Moleculin Biotech, Inc. (NASDAQ:MBRX) Q1 2025 Earnings Call Transcript - Insider Monkey
Moleculin Biotech Inc (MBRX) Q1 2025 Earnings Call Highlights: Strategic Advances and Financial ... - Yahoo Finance
Moleculin Biotech Inc (MBRX) Q1 2025 Earnings Call Highlights: S - GuruFocus
Moleculin Biotech Reports Q1 2025 Financial Results - TipRanks
Moleculin Biotech Gets EMA Nod For Leukemia Trial: Retail Feels Bullish On ‘Low And Slow’ Setup - MSN
Transcript : Moleculin Biotech, Inc., Q1 2025 Earnings Call, May 14, 2025 - marketscreener.com
Earnings call transcript: Moleculin Biotech reports Q1 2025 updates By Investing.com - Investing.com India
Earnings call transcript: Moleculin Biotech reports Q1 2025 updates - Investing.com
0.39%
0.42%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):